397 related articles for article (PubMed ID: 32514751)
1. Cannabidiol for Adjuvant Treatment of Seizures Associated with Lennox-Gastaut Syndrome and Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Wijnen B; Armstrong N; Ramaekers B; Witlox W; Westwood M; Fayter D; Ryder S; Buksnys T; Worthy G; Misso K; Grimm S; Kleijnen J; Joore M
Pharmacoeconomics; 2020 Oct; 38(10):1043-1053. PubMed ID: 32514751
[TBL] [Abstract][Full Text] [Related]
2. Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Wijnen B; Witlox W; Wolff R; Fayter D; Ramaekers B; Otten T; Ryder S; Posadzki P; Worthy G; Stirk L; Armstrong N; Kleijnen J; Joore M
Pharmacoeconomics; 2023 Jan; 41(1):33-42. PubMed ID: 36301414
[TBL] [Abstract][Full Text] [Related]
3. Retrospective chart review study of use of cannabidiol (CBD) independent of concomitant clobazam use in patients with Lennox-Gastaut syndrome or Dravet syndrome.
Nabbout R; Arzimanoglou A; Auvin S; Berquin P; Desurkar A; Fuller D; Nortvedt C; Pulitano P; Rosati A; Soto V; Villanueva V; Cross JH
Seizure; 2023 Aug; 110():78-85. PubMed ID: 37331197
[TBL] [Abstract][Full Text] [Related]
4. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
5. Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Tappenden P; Simpson E; Hamilton J; Pollard D; Clowes M; Kaltenthaler E; Meiklejohn D; Morley N
Pharmacoeconomics; 2019 Mar; 37(3):333-343. PubMed ID: 30246228
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
[TBL] [Abstract][Full Text] [Related]
7. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ
Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
[TBL] [Abstract][Full Text] [Related]
8. Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Ramaekers BLT; Riemsma R; Tomini F; van Asselt T; Deshpande S; Duffy S; Armstrong N; Severens JL; Kleijnen J; Joore MA
Pharmacoeconomics; 2017 Feb; 35(2):191-202. PubMed ID: 27566699
[TBL] [Abstract][Full Text] [Related]
9. Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal.
Pennington B; Ren S; Barton S; Bacelar M; Edwards SJ
Pharmacoeconomics; 2019 Aug; 37(8):985-993. PubMed ID: 30465228
[TBL] [Abstract][Full Text] [Related]
10. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Fleeman N; Abdulla A; Bagust A; Beale S; Richardson M; Stainthorpe A; Boland A; Kotas E; McEntee J; Palmer D
Pharmacoeconomics; 2018 Mar; 36(3):289-299. PubMed ID: 29178025
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
[TBL] [Abstract][Full Text] [Related]
12. Cannabidiol in conjunction with clobazam: analysis of four randomized controlled trials.
Gunning B; Mazurkiewicz-Bełdzińska M; Chin RFM; Bhathal H; Nortvedt C; Dunayevich E; Checketts D
Acta Neurol Scand; 2021 Feb; 143(2):154-163. PubMed ID: 32969022
[TBL] [Abstract][Full Text] [Related]
13. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials.
Bialer M; Perucca E
Epilepsia; 2020 Jun; 61(6):1082-1089. PubMed ID: 32452568
[TBL] [Abstract][Full Text] [Related]
14. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Bermejo I; Ren S; Simpson E; Clowes M; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Dec; 36(12):1427-1437. PubMed ID: 29882210
[TBL] [Abstract][Full Text] [Related]
15. Highly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox-Gastaut Syndrome.
Lattanzi S; Trinka E; Striano P; Rocchi C; Salvemini S; Silvestrini M; Brigo F
CNS Drugs; 2021 Mar; 35(3):265-281. PubMed ID: 33754312
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
[TBL] [Abstract][Full Text] [Related]
17. Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Otten T; Riemsma R; Wijnen B; Armstrong N; Stirk L; Gordon C; Ramaekers B; Kleijnen J; Joore M; Grimm S
Pharmacoeconomics; 2022 Sep; 40(9):851-861. PubMed ID: 35802295
[TBL] [Abstract][Full Text] [Related]
18. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
19. Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Stevenson M; Pandor A; Hamilton J; Stevens J; Rowntree C; Martyn-St James M; Rawdin A; Wong R
Pharmacoeconomics; 2018 Jul; 36(7):759-768. PubMed ID: 29502175
[TBL] [Abstract][Full Text] [Related]
20. Oral Azacitidine for Maintenance Treatment of Acute Myeloid Leukaemia After Induction Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Witlox W; Grimm S; Howick J; Armstrong N; Ahmadu C; McDermott K; Otten T; Noake C; Wolff R; Joore M
Pharmacoeconomics; 2023 Aug; 41(8):857-867. PubMed ID: 37129774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
